For the Inventor, By the Inventor

Enter assignee name

Mountain View, CA, United States of America

Edison Pharmaceuticals, Inc.

USPTO Granted Patents = 28

% Expired Patents = 50.0

EPO Patents = 6

Forward Citations = 637

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Kieron E Wesson (13 out of 26 patents)

Orion D Jankowski (11 out of 20 patents)

Andrew W Hinman (9 out of 22 patents)

4. Paul Mollard (9 out of 26 patents)

5. Guy M Miller (9 out of 22 patents)

6. William Dvorak Shrader (7 out of 22 patents)

7. Bing Wang (3 out of 64 patents)

8. Viktoria Kheifets (3 out of 15 patents)

9. Sidney M Hecht (3 out of 57 patents)

10. Gail Walkinshaw (3 out of 7 patents)

11. Jiangao Song (2 out of 24 patents)

12. Donald R James (2 out of 20 patents)

13. Xianming Jin (2 out of 2 patents)

14. Wei Zhang (2 out of 217 patents)

15. Jian Chen (2 out of 65 patents)

Core Competencies:

Alpha Tocotrienol

Mitochondrial Diseases

Redox-Active Therapeutics

Oxidative Stress

Catechol Derivatives

Quinone Derivatives

Energy Biomarkers

Pervasive Developmental Disorders

28 patents: Sort by Forward Citations

1. 9567279 - Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols (2017-02-14),

2. 9546132 - 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases (2017-01-17),

3. 9486435 - (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases (2016-11-08),

4. 9464016 - Catechol derivatives for treatment of oxidative stress diseases (2016-10-11),

5. 9447006 - Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers (2016-09-20),

6. 9399612 - Treatment of pervasive developmental disorders with redox-active therapeutics (2016-07-26),

7. 9370496 - Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones (2016-06-21),

8. 9296712 - Resorufin derivatives for treatment of oxidative stress disorders (2016-03-29),

9. 9278085 - Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers (2016-03-08),

10. 9169196 - 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases (2015-10-27),

11. 9162957 - Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols (2015-10-20),

12. 9090576 - [object Object] (2015-07-28),

13. 9073873 - 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases (2015-07-07),

14. 8969420 - Treatment of pervasive developmental disorders with redox-active therapeutics (2015-03-03),

15. 8952071 - (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases (2015-02-10),

Company Overview

Edison Pharmaceuticals, Inc. is a biotechnology company based in Mountain View, California, focused on developing innovative therapies for rare genetic diseases. The company specializes in leveraging advanced scientific research to create targeted treatments that address unmet medical needs. With a commitment to improving patient outcomes, Edison Pharmaceuticals emphasizes the importance of precision medicine and collaborates with various stakeholders to advance its research initiatives and bring new solutions to the market.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

28 Patents

#109 in Mountain View, CA

#2,846 in California

#12,009 in US

#23,262 in the World

Mountain View, CA, United States of America

Edison Pharmaceuticals, Inc.

Forward Citations = 637

24 inventors:

Kieron E Wesson (13 out of 26 patents)

Orion D Jankowski (11 out of 20 patents)

Andrew W Hinman (9 out of 22 patents)

4. Paul Mollard (9 out of 26 patents)

5. Guy M Miller (9 out of 22 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Edison Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/edison-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…